16Oct/18

Roche and SQZ Biotech Expand Cell Therapy Partnership to Develop Antigen Presenting Cells

SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, is expanding its collaboration with Roche in cellular therapy. Under the terms, SQZ and Roche will jointly develop andRead More…

12Sep/18

Chasing top HIV players, Merck scores FDA approval for 2 new drugs

After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside reverse transcriptase inhibitor calledRead More…

13Aug/18

FDA Grants Breakthrough Therapy Designation For Food Allergy Med

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Genentech’s,Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies.Read More…

14May/18

FDA Grants Priority Review of Genentech’s Tecentriq

Genentech, a member of the Roche Group today announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxelRead More…

16Apr/18

Lonza Opens World’s Largest Dedicated Cell And Gene Therapy Manufacturing Facility

Lonza opened the world’s largest dedicated cell and gene therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies—believed to be the next era inRead More…